%0 Journal Article %A Chandler D. Gatenbee %A NĂºria Folguera-Blasco %A Charlie Daneils %A Jill Gallaher %A Russ Rockne %A Casey Adams %A Michael Nicholson %A Eleni Maniati %A John Kennedy %A Kimberly Luddy %A Frederick L. Locke %A Mark Robertson-Tessi %T Exploiting Homeostatic Repopulation to Increase DC Vaccine Efficacy in Multiple Myeloma %D 2016 %R 10.1101/049072 %J bioRxiv %P 049072 %X Standard of care for multiple myeloma involves au-tologous hematopoietic cell transplant (AHCT), which can extend life by a year; however the disease remains incurable. A dendritic cell vaccine developed at Moffitt will be used both immediately before and after AHCT, with the aim of achieving complete response. Data will be collected during the trial to test the biological activity of the vaccine. This data will parameterize a model that facilitates the exploration of outcomes when varying the timing of vaccination. This calibrated model will also inform the design of a follow-up trial, which will include vaccination in conjunction with other immunotherapies. %U https://www.biorxiv.org/content/biorxiv/early/2016/04/22/049072.full.pdf